Musculoskeletal Pain Market Size Anticipated to Surge with a Significant CAGR of 22.5% in the 7MM During the Study Period [2018-30], Investigates DelveInsight

An increasing prevalence of Musculoskeletal Pain, novel and emerging pipeline therapies, awareness of the disease, and giant pharmaceutical entrants like Eli Lilly and Company, Sun Pharma Global FZE, Regeneron Pharmaceutical, Teva Pharmaceutical Industries shall propel the Musculoskeletal Pain market during the forecast period.

LAS VEGAS, Nov. 3, 2021 /PRNewswire/ -- DelveInsight's Musculoskeletal Pain Market Insights report provides a thorough understanding of current treatment practices, emerging drugs, Musculoskeletal Pain market share of the individual therapies, current and forecasted Musculoskeletal Pain market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan). 

Several essential outcomes extracted from the Musculoskeletal Pain Market Report: 

• As per DelveInsight's analysis, the Musculoskeletal Pain market size was 3647.2 million in 2020 and is expected to escalate with a substantial CAGR of 22.5% in the 7MM during the forecast period
• Key pharma players working proactively in the Musculoskeletal Pain therapeutic market are Eli Lilly and Company, AstraZeneca, Sun Pharma Global FZE, Flexion Therapeutics, Tonix Pharmaceuticals, Taisho Pharmaceutical, Anika Therapeutics, Mesoblast, Regeneron Pharmaceutical, Novartis Pharmaceuticals, Teva Pharmaceutical Industries, Mitsubishi, Tanabe Pharma, Sorrento Therapeutics, Braeburn Pharmaceuticals, Taiwan Liposome Company, Axsome Therapeutics, Techfields Pharma, Biosplice Therapeutics, Centrexion Therapeutics, Ampio Pharmaceuticals, Virios Therapeutics, Camurus, Kolon TissueGene, Amzell, Seikagaku Corporation, Propella Therapeutics, Moebius Medical, Antibe Therapeutics, Aesculap Biologics, VivaTech, Xalud Therapeutics, ACADIA Pharmaceuticals, Charleston Laboratories, and others have the potential to create a significant positive shift in the market size.
• The launch of emerging therapies in the Musculoskeletal Pain domain like Rexlemestrocel-L/MPC-06-ID, Fasinumab/REGN475/MT-5547, TLC599, LY3016859, RTX (resiniferatoxin), LY3556050, TG-C, IMC-1, AXS-14, Lorecivivint, CNTX-4975, X0002, Ampion, CAM2028, JOYCLU, AMZ001, XT-150, TNX-102 SL, CGS-200-5, DFV890, StroMed + platelet-rich plasma, Fremanezumab, Canakinumab, MM-II, Otenaproxesul, NOVOCART 3D, ACP-044, MEDI7352, CL-108, ZILRETTA, and others will significantly impact the Musculoskeletal Pain market during the forecast period.
• As per DelveInsight's analyst, the emerging market for Musculoskeletal Pain is promising, consisting of many key assets such as Ampion, CAM2038, CNTX-4975, Fasinumab, Rexlemestrocel-L, lorecivivint, and TG-C. Among these, lorecivivint and TG-C may potentially prevent cartilage deterioration and are thus disease-modifying OA drugs (DMOADs). DelveInsight believes that these DMOADs can address the current unmet needs and be potential game-changers in the treatment of Musculoskeletal Pain during the forecast period.
• It is expected that the therapeutic market size of Musculoskeletal Pain is expected to change significantly after the launch of various novel therapies, the increasing prevalence of Musculoskeletal Pain, awareness of the disease, and promising as well as emerging new pipeline therapies will propel the Musculoskeletal Pain market.

Discover more about therapies set to grab substantial Musculoskeletal Pain market share @ Musculoskeletal Pain Market Landscape 

Musculoskeletal Pain: Overview 

Musculoskeletal pain is defined as acute or chronic pain that affects bones, muscles, ligaments, tendons, and even nerves. Musculoskeletal pain (in particular, low back pain) is the main contributor to disability worldwide. According to the World Health Organization (WHO), 20–33% of the world's population has some form of Musculoskeletal Pain, translating to 1.75 billion people globally.

Musculoskeletal Pain Epidemiology Segmentation

As per DelveInsight, the total diagnosed prevalent cases of Musculoskeletal Pain in the 7MM in 2020 were 145,426,730 cases.

In 2020, the diagnosed prevalent cases of Musculoskeletal Pain in the United States were 76,331,935 cases, which as per DelveInsight's estimates, is projected to increase by 2030.

The Musculoskeletal Pain Market Report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

• Diagnosed Prevalent Cases of Musculoskeletal Pain
• Gender-specific Cases of Musculoskeletal Pain
• Age-specific Cases of Musculoskeletal Pain

Download report to understand which demographic factors are guiding Musculoskeletal Pain epidemiology trends @ Musculoskeletal Pain Epidemiological Insights 

Musculoskeletal Pain Market

Traditionally, NSAIDs were used for the treatment of Musculoskeletal Pain. The overall strength of evidence based on different studies is moderate. However, there is moderate evidence that pharmacological therapies are beneficial for the short-term relief of Musculoskeletal Pain. Thus, NSAIDs, Cox-2 selective inhibitors, and opioids reduce pain in the short term, but the effect size is modest, and the potential for adverse effects such as gastrointestinal bleeding and opioids-induced hyperalgesia need careful consideration. 

Mainly analgesics and opioids are used to treat Musculoskeletal Pain, but some adjuvants are most widely used, like corticosteroids, anticonvulsants, anxiolytics, and antidepressants. Zilretta, Cingal, Cymbalta, Drizalma Sprinkle, and Loqoa Tape are the marketed drugs for Musculoskeletal Pain.

Currently, pipeline products in clinical development include Mesoblast' Rexlemestrocel-L, Regeneron

Pharmaceuticals/Teva Pharmaceutical Industries' fasinumab, Taiwan Liposome Company's TLC599, and others. Other assets include drugs such as ACP-044, MEDI7352, CL-108, XT-150, and many more. It is expected that the launch of these drugs is likely to expand market size during the forecast period due to an increase in treatment pool and disease awareness.

Learn more about the current and emerging treatments @ Musculoskeletal Pain Market Analysis

Musculoskeletal Pain Market: Drivers and Barriers

A robust pipeline of novel potential therapies is existent as many pharmaceutical companies are continuously researching and innovating the treatment regimens for eradicating the current unmet needs in Musculoskeletal Pain. The discovery of new pathogenic mechanisms serves as some of the major factors for the Musculoskeletal Pain Market surge in the coming years.  Increased prevalence, as well as increasing awareness regarding the disease, a multidisciplinary approach, strong patient education of musculoskeletal disorders, pain syndromes to improve care, and the possibility of a long-term cure also add to the anticipated rise of Musculoskeletal Pain Market.

Whereas, the presence of off-label drugs usage, unspecific assessment of Musculoskeletal Pain, and misclassification act as certain drawbacks for the growth of the Musculoskeletal Pain Market. Even after decades of research, chronic Musculoskeletal Pain conditions underlying etiology and pathology are poorly understood.

Scope of the Musculoskeletal Pain Market Report

• Study Period: 2018-30
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Companies: Eli Lilly and Company, Sun Pharma Global FZE, Flexion Therapeutics, AstraZeneca, Taisho Pharmaceutical, Anika Therapeutics, Mesoblast, Regeneron Pharmaceutical, Teva Pharmaceutical Industries, Mitsubishi,  Tonix Pharmaceuticals, Tanabe Pharma, ACADIA Pharmaceuticals, Xalud Therapeutics, Sorrento Therapeutics, Taiwan Liposome Company, Axsome Therapeutics, Biosplice Therapeutics, Moebius Medical, Propella Therapeutics, Centrexion Therapeutics, Ampio Pharmaceuticals, Antibe Therapeutics, Techfields Pharma, Virios Therapeutics, Camurus, Novartis Pharmaceuticals, Braeburn Pharmaceuticals, Kolon TissueGene, Amzell, Seikagaku Corporation, Aesculap Biologics, VivaTech, Charleston Laboratories.
• Key Musculoskeletal Pain Pipeline Therapies: Rexlemestrocel-L/MPC-06-ID, Fasinumab/REGN475/MT-5547, TLC599, LY3016859, RTX (resiniferatoxin), LY3556050, TG-C, IMC-1, AXS-14, Lorecivivint, CNTX-4975, X0002, Ampion, CAM2028, JOYCLU, AMZ001, XT-150, TNX-102 SL, CGS-200-5, DFV890, StroMed + platelet-rich plasma, Fremanezumab, Canakinumab, MM-II, Otenaproxesul, NOVOCART 3D, ACP-044, MEDI7352, CL-108, ZILRETTA, and others.
• Therapeutic Assessment: Musculoskeletal Pain current marketed and emerging therapies
• Market Dynamics: Musculoskeletal Pain market drivers and barriers 
• Key Cross Competition
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs
• Case Studies
• KOL's Views
• Analyst's Views
• Market Access and Reimbursement Scenario

Get in touch with our Business executive @ Musculoskeletal Pain Market Landscape Analysis 

Table of Contents

Learn more about the report offerings @ Musculoskeletal Pain Market Outlook

Related Reports

Chronic Pain associated with Painful Diabetic Neuropathy Market

DelveInsight's 'Chronic Pain associated with Painful Diabetic Neuropathy- Market Insight, Competitive Landscape and Market Forecast, 2026' report delivers an in-depth understanding of Chronic Pain associated with Painful Diabetic Neuropathy and the historical and forecasted Chronic Pain associated with Painful Diabetic Neuropathy market trends, market drivers, market barriers and key companies involved like Janssen Pharmaceuticals, Grunethal, Pfizer, Eli Lilly and Shionogi, Ono pharmaceuticals, Fremslife S.r.l, Helixmith, Aptinyx, Regenacy Pharmaceuticals, and others.

Complex Regional Pain Syndrome Market

DelveInsight's 'Complex Regional Pain Syndrome (CRPS) - Market Insights, Epidemiology and Market Forecast—2030' report delivers an in-depth understanding of the CRPS, historical and forecasted epidemiology, market drivers, market barriers and key companies involved like Ovid Therapeutics, Takeda, AstraZeneca, Biohaven Pharmaceutical, and others.

Postoperative Pain Market 

DelveInsight's 'Postoperative Pain-Market Insights, Epidemiology, and Market Forecast–2030' report deliver an in-depth understanding of the postoperative pain, historical and forecasted epidemiology market access, and key companies involved like Trevena, Inc, Heron Therapeutics, Innocoll Pharmaceuticals, DURECT Corporation, Pacira Pharmaceuticals, Bausch & Lomb, Ocular Therapeutix, Kala Pharmaceuticals, Inc, Unither Pharmaceuticals, Esteve Pharmaceuticals, Formosa Pharmaceuticals, and others.

Complex Regional Pain Syndrome Market

DelveInsight's 'Complex Regional Pain Syndrome (CRPS) - Market Insights, Epidemiology and Market Forecast—2030' report delivers an in-depth understanding of the CRPS, historical and forecasted epidemiology, market drivers, market barriers and key companies involved like Ovid Therapeutics, Takeda, AstraZeneca, Biohaven Pharmaceutical, and others.

Chronic Lower Back Pain Market 

DelveInsight's 'Chronic Lower Back Pain (CLBP) Market Insights, Epidemiology and Market Forecast–2030' report delivers an in-depth understanding of the Chronic lower back pain (CLBP), historical and forecasted epidemiology, market drivers, market barriers and key companies involved like Eli Lilly and Company, Collegium Pharmaceutical, Purdue Pharma, BioDelivery Sciences International, Pfizer, Regeneron Pharmaceuticals, Teva Pharmaceuticals, Mesoblast, and others.

Acute Ocular Pain Market

DelveInsight's 'Acute Ocular Pain (AOP)-Market Insights, Epidemiology, and Market Forecast–2030' report deliver an in-depth understanding of the AOP, historical and forecasted epidemiology, market drivers, market barriers, and key companies involved like Ocular Therapeutix, Kala Pharmaceuticals, Sun Pharmaceutical, Bausch & Lomb, Formosa Pharmaceuticals, Aldeyra Therapeutics, and others.

Chronic Pain Market

DelveInsight's 'Chronic Pain - Market Insights, Epidemiology, and Market Forecast—2030' report delivers an in-depth understanding of Chronic Pain, historical and forecasted epidemiology, market drivers, market barriers, and key companies involved like Eli Lilly and Company, Samumed, Sorrento Therapeutics, Ampio Pharmaceuticals, Semnur Pharmaceuticals, Braeburn Pharmaceuticals/Camurus, Taiwan Liposome Company, Centrexion Therapeutics, Biogen, and others.

Browse Through Our Blog Posts

Musculoskeletal Disorders Key Companies

Some of the key companies such as Braeburn Pharmaceuticals, Astellas Pharma, Camurus, Regeneron Pharmaceuticals, Stayble Therapeutics, Teva Pharmaceutical, Pfizer, Eli Lilly and Company, Mesoblast, and others diligently working toward the development of new Musculoskeletal Disorders therapies.

Musculoskeletal disorders based Reports

Musculoskeletal disorders are injuries or pain in the body's joints, ligaments, muscles, nerves, tendons, and structures that support limbs, neck and back.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect With Us at LinkedIn | Facebook | Twitter

Contact Us
Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com   

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg